New Zealand markets closed

AbbVie Inc. (ABBV)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
109.14+0.38 (+0.35%)
At close: 4:02PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close108.76
Open108.67
Bid0.00 x 2200
Ask0.00 x 900
Day's range108.31 - 109.22
52-week range79.11 - 121.53
Volume4,346,878
Avg. volume7,141,750
Market cap192.87B
Beta (5Y monthly)0.83
PE ratio (TTM)29.43
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield5.20 (4.76%)
Ex-dividend date14 Oct 2021
1y target estN/A
All
News
  • Business Wire

    Clinical Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory B-cell non-Hodgkin’s Lymphoma (B-NHL) Published in The Lancet

    COPENHAGEN, Denmark & NORTH CHICAGO, Ill., September 09, 2021--Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) today announced The Lancet published the results of the dose escalation part of the phase 1/2 EPCORE™ NHL-1 first-in-human (FIH) dose escalation and cohort expansion clinical trial evaluating safety and preliminary efficacy of the investigational therapy epcoritamab (DuoBody®-CD3xCD20) in patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma (B-NHL). The full manuscript is a

  • GlobeNewswire

    Collaboration Between AbbVie, Biogen and Pfizer Creates World’s Largest Browsable Resource Linking Rare Protein-Coding Genetic Variants to Human Health and Disease

    CAMBRIDGE, Mass. and NEW YORK, July 08, 2021 (GLOBE NEWSWIRE) -- Today, access to the world’s largest browsable resource linking rare protein-coding genetic variants to human health and disease was launched through a genetic exome sequence analysis collaboration between AbbVie (NYSE: ABBV), Biogen Inc. (Nasdaq: BIIB) and Pfizer (NYSE: PFE). Managed by the Broad Institute of MIT and Harvard, the browser gives access to results from analyses of whole exome sequencing data from 300,000 UK Biobank r

  • GlobeNewswire

    SOLITON ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of SOLY and Encourages Investors to Contact the Firm

    NEW YORK, May 11, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Soliton, Inc. (NASDAQ: SOLY) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by AbbVie, Inc. (NYSE: ABBV). Click here to learn more and participate in the action. On May 10, 2021, Soliton announced that it had signed an agreement to be acquired by AbbVie for approximately $550 million. Pursuant to the merger agreement, Soliton stockholders will receive $22.60 in cash for each share of Soliton common stock owned. Bragar Eagel & Squire is concerned that Soliton’s board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement. Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for Soliton’s stockholders. If you own shares of Soliton and are concerned about the proposed merger, or you are interested in learning more about the investigation or your legal rights and remedies, please contact Melissa Fortunato or Alexandra Raymond by email at investigations@bespc.com or telephone at (646) 860-9157, or by filling out this contact form. There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.:Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes. Contact Information:Bragar Eagel & Squire, P.C.Melissa Fortunato, Esq.Alexandra Raymond, Esq.investigations@bespc.comwww.bespc.com